Status:

COMPLETED

A Study to Assess Usability of Risankizumab Autoinjector Combination Product in Participants With Moderate to Severe Plaque Psoriasis

Lead Sponsor:

AbbVie

Conditions:

Psoriasis

Eligibility:

All Genders

18+ years

Phase:

PHASE3

Brief Summary

The objectives of this study were to evaluate the usability of the combination product of risankizumab in an autoinjector (AI), as well as to evaluate the efficacy, safety, and tolerability of risanki...

Detailed Description

This was a Phase 3 multicenter, single-arm, open-label study that evaluated usability and efficacy of the risankizumab-AI combination product. The study included a 30-day screening period with study v...

Eligibility Criteria

Inclusion

  • Participant has diagnosis of chronic plaque psoriasis for at least 6 months before the baseline visit
  • Participant meets following disease activity criteria:
  • Stable moderate to severe chronic plaque psoriasis, defined as ≥ 10% body surface area (BSA) psoriasis involvement, static Physician Global Assessment (sPGA) score ≥ 3, and Psoriasis Area Severity Index (PASI) ≥ 12 at Screening and baseline visit
  • Candidate for systemic therapy as assessed by the investigator

Exclusion

  • Participant has history of active skin disease other than psoriasis that could interfere with the assessment of psoriasis
  • Participant has history of erythrodermic psoriasis, generalized or localized pustular psoriasis, medication-induced or medication-exacerbated psoriasis, or new onset guttate psoriasis
  • Participant has previous exposure to risankizumab

Key Trial Info

Start Date :

June 4 2019

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

August 25 2020

Estimated Enrollment :

108 Patients enrolled

Trial Details

Trial ID

NCT03875508

Start Date

June 4 2019

End Date

August 25 2020

Last Update

May 11 2021

Active Locations (26)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 7 (26 locations)

1

Advanced Research Associates /ID# 210634

Glendale, Arizona, United States, 85308

2

Cognitive Clinical Trials /ID# 210770

Scottsdale, Arizona, United States, 85258-4446

3

Burke Pharmaceutical Research /ID# 211386

Hot Springs, Arkansas, United States, 71913-6404

4

Bakersfield Derma & Skin Cance /ID# 210773

Bakersfield, California, United States, 93309